NRXS (Neuraxis) GF Score: 42/100 (As of Jul. 15, 2026) — 147% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRXS Neuraxis Inc NRXS
42 GF Score
Price $6.98
GF Value $2.93
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Neuraxis GF Score?

Neuraxis NRXS -2.38% 42 GF Score is 42 as of Jul. 15, 2026, which is 147% above its 10-year median of 17.00. GuruFocus rates NRXS with a GF Score™ of 42/100 and a GF Value™ of $2.93 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Neuraxis has the GF Score of 42, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 2/10
3. Growth Rank : 8/10
4. GF Value Rank : 1/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Neuraxis might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Neuraxis  (AMEX:NRXS) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Neuraxis GF Score Related Terms

NRXS vs PYPD, INO, FBIO: GF Score Comparison

For the Biotechnology subindustry, Neuraxis's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuraxis GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's GF Score distribution charts can be found below:

* The bar in red indicates where Neuraxis's GF Score falls into.


NRXS
42GF Score
Neuraxis Inc NRXS
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 42 mean?
Neuraxis (NRXS) has a GF Score of 42 as of Jul. 15, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Neuraxis and its competitors. This is 147% above median its historical median of 17.00. Over the past decade, Neuraxis' GF Score has ranged from 10.00 to 47.00.
Is Neuraxis' GF Score too high?
Neuraxis' current GF Score of 42 is 147% above median its 10-year median of 17.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 47.00. Overall, Neuraxis has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuraxis' GF Score compare to PYPD and INO?
Neuraxis' GF Score of 42 can be compared against companies in the Biotechnology industry. Historically, Neuraxis' own GF Score has ranged from 10.00 to 47.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Neuraxis and its competitors. Neuraxis's current GF Score is 42, which is 147% above median its own 10-year median of 17.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuraxis stock overvalued right now?
Based on GuruFocus' analysis, Neuraxis (NRXS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.93, compared to a current price of $6.98 — trading 138.2% above its estimated fair value. The current GF Score is 42, which is 147% above median its 10-year median of 17.00. Neuraxis' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Neuraxis (NRXS), the current GF Score is 42 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuraxis (NRXS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuraxis stock appears to be overvalued. The current stock price of $6.98 is trading 138.2% above its estimated GF Value™ of $2.93. GuruFocus considers Neuraxis to be Significantly Overvalued.

Key valuation signals for NRXS:

  • GF Score: 42 (147% above median its 10-year median of 17.00)
  • GF Value™: $2.93 vs. price of $6.98 (138.2% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the NRXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuraxis Business Description

Address 11611 North Meridian Street, Suite 330, Carmel, IN, USA, 46032
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
42GF Score

Get the complete analysis for NRXS

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.98
Price
$2.93
GF Value